Inactive Instrument

Rubius Therapeutics

Equities

RUBY

US78116T1034

RUBIUS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)

October 17, 2022 at 09:08 pm

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 17, 2022, David Epstein resigned from his position as a member of the Board and any committees thereof, effective immediately. Mr. Epstein's resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

Latest news about Rubius Therapeutics

North American Morning Briefing : Stock Futures -2-	22/08/23	DJ
North American Morning Briefing : China Angst -2-	15/08/23	DJ
North American Morning Briefing : Sentiment Hit by -2-	08/08/23	DJ
North American Morning Briefing : Latest China -2-	01/08/23	DJ
North American Morning Briefing : Alphabet, -2-	25/07/23	DJ
North American Morning Briefing : Fresh Batch of -2-	18/07/23	DJ
North American Morning Briefing : Beijing Boost Supports Mood; CPI Still The Main Event	11/07/23	DJ
North American Morning Briefing : Stock Futures -2-	27/06/23	DJ
North American Morning Briefing : Stock Futures -2-	20/06/23	DJ
North American Morning Briefing : Investors Brace -2-	13/06/23	DJ
North American Morning Briefing : Stocks Poised -2-	30/05/23	DJ
North American Morning Briefing : Stock Futures -2-	23/05/23	DJ
North American Morning Briefing : Retail Sales, -2-	16/05/23	DJ
Rubius Therapeutics, Inc. Announces Resignation of Pablo J. Cagnoni, M.D. as Member of Board of Directors	06/04/23	CI
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from S&P TMI Index	09/03/23	CI
Upcoming Powell Testimony to Congress Underpins US Equity Futures	06/03/23	MT
Top Premarket Decliners	06/03/23	MT
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from NASDAQ Composite Index	06/03/23	CI
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell 3000E Index	06/03/23	CI
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell Microcap Value Index	06/03/23	CI
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell 3000E Value Index	06/03/23	CI
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell Microcap Index	06/03/23	CI
Rubius Therapeutics, Inc. Announces Board Changes	03/03/23	CI
Rubius Therapeutics, Inc. Announces CEO Changes	03/03/23	CI
Rubius Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI

Chart Rubius Therapeutics

Duration

Period

More charts

Company Profile

Rubius Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing a platform and pipeline that is focused on creating cellular medicines called Red Cell Therapeutics. The Company's Red Cell Therapeutics are engineered to express biotherapeutic proteins within or on their cell surface to create selective and allogeneic cellular medicines for treating a range of diseases. Red Cell Therapeutics can also be used to kill tumors in cancer, regulate the immune system for the treatment of autoimmune diseases and treat a number of other types of illnesses. The Company's subsidiary is Rubius Therapeutics Securities Corporation.

Sector

More about the company